Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design

Open access
Sheikh, Aziz, Kerr, Steven, Woolhouse, Mark, McMenamin, Jim, Robertson, Chris, Simpson, Colin Richard, Millington, Tristan, Shi, Ting, Agrawal, Utkarsh, Shahul Hameed, Safraj, Hall, Elliott, Rudan, Igor, Shah, Syed Ahmar, Ritchie, Lewis, Stock, Sarah, McCowan, Colin·2022·The Lancet Infectious Diseases

Abstract

BACKGROUND: Since its emergence in November, 2021, in southern Africa, the SARS-CoV-2 omicron variant of concern (VOC) has rapidly spread across the world. We aimed to investigate the severity of omicron and the extent to which booster vaccines are effective in preventing symptomatic infection. METHODS: In this study, using the Scotland-wide Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, we did a cohort analysis with a nested test-negative design incident case-control study covering the period Nov 1-Dec 19, 2021, to provide initial estimates of omicron severity and the effectiveness of vaccine boosters against symptomatic disease relative to 25 weeks or more after the second vaccine dose. Primary care data derived from 940 general practices across Scotland were linked to laboratory data and hospital admission data. We compared outcomes between infection with the delta VOC (defined as S-gene positive) and the omicron VOC (defined as S-gene negative). We assessed effectiveness against symptomatic SARS-CoV-2 infection, with infection confirmed through a positive RT-PCR. FINDINGS: By Dec 19, 2021, there were 23 840 S-gene-negative cases in Scotland, which were predominantly among those aged 20-39 years (11 732 [49·2%]). The proportion of S-gene-negative cases that were possible reinfections was more than ten times that of S-gene-positive cases (7·6% vs 0·7%; p<0·0001). There were 15 hospital admissions in S-gene-negative individuals, giving an adjusted observed-to-expected admissions ratio of 0·32 (95% CI 0·19-0·52). The booster vaccine dose was associated with a 57% (54-60) reduction in the risk of symptomatic S-gene-negative infection relative to individuals who tested positive 25 weeks or more after the second vaccine dose. INTERPRETATION: These early national data suggest that omicron is associated with a two-thirds reduction in the risk of COVID-19 hospitalisation compared with delta. Although offering the greatest protection against delta, the booster dose of vaccination offers substantial additional protection against the risk of symptomatic COVID-19 for omicron compared with 25 weeks or more after the second vaccine dose. FUNDING: Health Data Research UK, National Core Studies, Public Health Scotland, Scottish Government, UK Research and Innovation, and University of Edinburgh.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(22)00141-4

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 10

  1. Viana, 2022, Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa, Nature, 603, 679, 10.1038/s41586-022-04411-y · DOI · Paper page
  2. Peacock, 2021, The SARS-CoV-2 variant, omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry, bioRxiv
  3. Meng, 2021, Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity, Nature
  4. Mulholland, 2021, Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database, Int J Epidemiol, 50, 1064, 10.1093/ije/dyab028 · DOI
  5. Sheikh, 2021, SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness, Lancet, 397, 2461, 10.1016/S0140-6736(21)01358-1 · DOI · Paper page
  6. Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 · DOI · Paper page
  7. Clift, 2020, Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study, BMJ, 371
  8. Breslow, 1987, Statistical methods in cancer research. Volume II—the design and analysis of cohort studies, IARC Sci Pub, 82, 1
  9. Katikireddi, 2022, Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil, Lancet, 399, 25, 10.1016/S0140-6736(21)02754-9 · DOI · Paper page
  10. Cele, 2022, Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization, Nature, 602, 654, 10.1038/s41586-021-04387-1 · doi:10.1038/s41586-021-04387-1 · Paper page

Cited by

See all 239

Metadata

Authors
Sheikh, A., Kerr, S., Woolhouse, M., McMenamin, J., Robertson, C., Simpson, C. R., Millington, T., Shi, T., Agrawal, U., Shahul Hameed, S., Hall, E., Rudan, I., Shah, S. A., Ritchie, L., Stock, S., & McCowan, C.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2022-07
Volume
22
Issue
7
Pages
959-966
ISSN
1473-3099 (ISSN-L)
OpenAlex
W4224287290
Cited by
239
References
7
FWCI
26.43
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. https://app.cochat.ai/papers/10.1016/s1473-3099(22)00141-4
The paper
Sheikh, A., Kerr, S., Woolhouse, M., McMenamin, J., Robertson, C., Simpson, C. R., Millington, T., Shi, T., Agrawal, U., Shahul Hameed, S., Hall, E., Rudan, I., Shah, S. A., Ritchie, L., Stock, S., & McCowan, C. (2022). Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(22)00141-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.